Augmenting the action of levodopa.
D000547:Amantadine / Q000627:therapeutic use; D000863:Antacids / Q000627:therapeutic use; D001058:Apomorphine / Q000009:adverse effects; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D065098:Catechol O-Methyltransferase Inhibitors; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004299:Dopamine beta-Hydroxylase / Q000037:antagonists & inhibitors; D004357:Drug Synergism; D006801:Humans; D008750:Methyldopa / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*
D000863:Antacids; D065098:Catechol O-Methyltransferase Inhibitors; D008996:Monoamine Oxidase Inhibitors; D010276:Parasympatholytics; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D000547:Amantadine; D004299:Dopamine beta-Hydroxylase; D002262:Carboxy-Lyases; D001058:Apomorphine